Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 82,465 Shares

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler acquired 82,465 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were bought at an average cost of $10.96 per share, with a total value of $903,816.40. Following the purchase, the director owned 1,463,210 shares in the company, valued at approximately $16,036,781.60. The trade was a 5.97% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Biodesix Trading Up 3.2%

Shares of BDSX traded up $0.38 during mid-day trading on Monday, hitting $12.12. The company had a trading volume of 133,451 shares, compared to its average volume of 5,179,934. Biodesix, Inc. has a 1-year low of $3.44 and a 1-year high of $21.80. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 41.11. The business’s 50-day simple moving average is $7.63 and its 200-day simple moving average is $7.66. The stock has a market cap of $96.44 million, a PE ratio of -2.16 and a beta of 0.60.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.60) by $0.44. The company had revenue of $21.77 million for the quarter, compared to analyst estimates of $20.98 million. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. Sell-side analysts forecast that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Institutional Trading of Biodesix

A number of hedge funds have recently made changes to their positions in the company. Aberdeen Group plc acquired a new stake in shares of Biodesix during the 4th quarter valued at approximately $1,784,000. XTX Topco Ltd increased its stake in Biodesix by 99.4% during the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after purchasing an additional 102,494 shares during the last quarter. Oracle Investment Management Inc. acquired a new stake in shares of Biodesix during the third quarter worth $113,000. Finally, Millennium Management LLC bought a new position in shares of Biodesix in the 3rd quarter worth about $113,000. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Wall Street Zen upgraded shares of Biodesix from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Biodesix currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.